| Category | Details |
|---|---|
| Active Ingredients | Sacubitril 97 mg + Valsartan 103 mg per tablet (200 mg total) |
| Indication | Chronic Heart Failure (NYHA Class II-IV) |
| US Brand | Entresto (Novartis) |
| Manufacturer | Novartis India Ltd. (Part of Novartis AG) |
| Packaging | 7 tablets/strip |
| Strength | Sacubitril 97 mg + Valsartan 103 mg |
| Delivery Time | 6–15 days |
🌟 Introduction to Vymada 200 mg (Sacubitril/Valsartan)
Vymada 200 mg by Novartis India is a dual-action therapy combining Sacubitril (neprilysin inhibitor) and Valsartan (ARB) to treat chronic heart failure. This innovative combo reduces strain on the heart by blocking harmful hormones (angiotensin II) and enhancing protective ones (natriuretic peptides). Clinical trials show it lowers hospitalization risk by 20% and cuts cardiovascular deaths by 16% compared to traditional therapies. Packaged in 7-tablet strips, Vymada offers a cost-effective alternative to Entresto, adhering to WHO-GMP standards.
🧪 Chemical Composition
| Component | Role |
|---|---|
| Sacubitril | Neprilysin inhibitor (97 mg) |
| Valsartan | Angiotensin II receptor blocker (103 mg) |
| Microcrystalline Cellulose | Binder/Stabilizer |
| Magnesium Stearate | Lubricant |
🏭 Manufacturer Spotlight: Novartis India
Novartis India, a subsidiary of Swiss pharma giant Novartis AG, is a leader in cardiovascular and oncology therapies. Founded in 1996, it operates under WHO-GMP, USFDA, and EU-GMP standards, exporting to 50+ countries. Vymada reflects its commitment to cutting-edge, affordable care.
🌍 How to Buy Vymada in the US, Australia & UK
United States:
-
Prescription Required: Yes (FDA-approved Entresto costs 500–600/month).
-
Cost Savings:
Source Price (28 tablets) US Brand (Entresto) 500–600 Vymada (India) 50–100
Australia/UK:
💡 Dosage & Usage
Recommended Dosage:
-
Starting Dose: 49/51 mg twice daily (titrate to 97/103 mg).
-
Maintenance: 200 mg (Sacubitril/Valsartan) twice daily.
Usage Tips:
🌀 Take 1 hour before/2 hours after meals for optimal absorption.
🌀 Avoid potassium supplements (risk of hyperkalemia).
⚠️ Side Effects & Precautions
| Common Effects (≤15% Users) | Rare Risks (≤2% Users) |
|---|---|
| Dizziness | Angioedema (facial swelling) |
| Hyperkalemia | Kidney dysfunction |
FDA Warning: Contraindicated in pregnancy (fetal toxicity) or with ACE inhibitors (FDA).
🔗 Internal Links to Indian Brands
-
Valzaar: Valsartan by Torrent Pharma.
-
Cardivas: Carvedilol for heart failure.
-
Lasix: Furosemide for edema.
-
Zyloric: Allopurinol for gout.
🩺 Expert Opinion: Dr. Arjun Patel
*“Vymada’s dual mechanism revolutionizes heart failure management. Novartis’ formulation matches Entresto’s efficacy but at 80% lower cost, making it a game-changer for patients needing long-term therapy.”*
— Dr. Arjun Patel, Cardiologist, Kokilaben Dhirubhai Ambani Hospital, Mumbai
📦 Storage Guide
| Condition | Requirement | Icon |
|---|---|---|
| Temperature | Below 30°C | 🌡️ |
| Moisture | Keep in original strip | 🛡️ |
| Light | Avoid exposure | 🌑 |
📝 Prescription Requirements
-
US/UK/AU: Mandatory. Use platforms like Practo for online consultations.
📊 Price Comparison: India vs. Global
| Country | Price (28 tablets) | Savings vs. US |
|---|---|---|
| India | ₹3,000–₹5,000 (40–67) | 80–85% |
| USA | 500–600 | — |
| UK | £400–£500 | 75–80% |
| Australia | AUD 600–AUD 800 | 70–75% |
Authoritative Resources:
🌟 Pro Tip: Pair Vymada with low-sodium diets and daily weight monitoring to manage heart failure effectively!

